Edwards Lifesciences (EW)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$89.90+0.13%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Edwards Lifesciences grows sales about 10% a year. Profit rises with EPS near $3.00 in 2026. TAVR sales expand steadily, reaching $1.2 billion in Q1 2026. The company benefits from a rival's setback, strengthening its market position.
Growth could slow if TAVR sales falter or competition intensifies. EPS might miss guidance if costs rise. Regulatory or leadership changes could disrupt execution.
The price is about 18% above our fair value near $80. Analysts expect 11.5% revenue growth, which aligns with company guidance. Our fair value is below the Street median, reflecting a cautious view on margin and growth sustainability.
Breaks if: EPS falls below $2.95 in FY 2026
Breaks if: Revenue falls below $6.5 billion in FY 2026
Breaks if: TAVR sales growth falls below 7% in FY 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on consistent growth in sales and market adoption. The current thesis state is intact, reflecting solid financial performance despite a medium confidence level.
The market seems to have priced in a premium compared to peers, indicating that expectations are somewhat high. However, the expectations gap is narrow, suggesting that the current valuation is justified given the company's recent performance.
Fundamentals are likely to remain stable as management continues to focus on achieving their growth targets. Recent financial results have been strong, but there is a moderate risk due to the potential for economic downturns affecting the sector.
The thesis hinges on the company's ability to maintain its growth trajectory and manage any potential guidance cuts. Additionally, the performance of sector peers and overall economic conditions will be critical in determining future outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Over the next 1 to 3 years, EW's performance will depend on its execution of growth strategies and external economic factors. Not investment advice.